Anti-VEGF treatment options for diabetic macular edema
Institute for Clinical and Economic Review (ICER)
Record ID 32015000933
English
Authors' objectives:
ICER completed a robust technology assessment of the treatment options for diabetic macular edema (DME) for the Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting on March 21, 2012. MEDCAC is reviewing the evidence on anti-vascular endothelial growth factor (anti-VEGF) treatment options for DME, a condition marked by progressive sight loss common in patients with diabetes. The technology assessment examined the evidence on Avastin, Eylea, Lucentis and Macugen.
Authors' recommendations:
ICER used its expertise in comparative effectiveness research to conduct a systematic review of the evidence on the clinical effectiveness and potential harms of intravitreal agents which inhibit VEGF in patients with DME.
MEDCAC provides independent guidance and expert advice to the Centers for Medicare and Medicaid Services (CMS) on specific clinical topics and provides judgments on the strength of the available evidence. MEDCAC then makes recommendations to CMS based on that evidence to help guide coverage policy.
Details
Project Status:
Completed
URL for project:
http://www.icer-review.org/dme/
Year Published:
2012
URL for published report:
http://www.icer-review.org/wp-content/uploads/2013/04/DME-Appraisal-Document-Master-File-with-Appendix_Corrected-Updated-02.01.1
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Diabetic Retinopathy
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Aptamers, Nucleotide
- Receptors, Vascular Endothelial Growth Factor
- Vascular Endothelial Growth Factor A
- Recombinant Fusion Proteins
- Intravitreal Injections
- Visual Acuity
Contact
Organisation Name:
Institute for Clinical and Economic Review
Contact Address:
101 Merrimac St., 10th FL., Boston MA, USA 02114, Tel: (617) 724-4445 , Fax: (617) 726-9414
Contact Name:
info@icer-review.org
Contact Email:
info@icer-review.org
Copyright:
Institute for Clinical and Economic Review (ICER)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.